en · de · es
sr9009-notes.peptides7501.com › Wiki › Background And Research Status — What the Evidence Shows

Background And Research Status — What the Evidence Shows

By Editorial Desk · published 2026-03-12 · last reviewed 2026-04-14 · Wiki

Everything below concerns SR9009. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Updated 2026-04-14. Numbers and descriptions here follow the published literature rather than marketing material.

Background and Research Status

REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.

Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.

SR9009 Identity and Mechanism

SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.

SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.

REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.

Sr9009 at a glance

PropertyValueNotes
Common nameSR9009Also referred to as Stenabolic in non-scientific contexts.
Chemical classSynthetic small moleculeNot a steroid or peptide hormone.
Receptor targetREV-ERBα and REV-ERBβNuclear receptor agonist in preclinical studies.
Development statusInvestigationalNo approved human therapeutic indication.
Regulatory attentionProhibited in sportListed by anti-doping authorities.

Analytical Detection and Regulatory Status

Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.

Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.

Related pages on this site

SR9009 Background and Mechanism

Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.

In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.

Analytical Detection and Stability

Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.

Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.

Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.

Notes from published material

acts as a self-standard. Ultramicroporous, microporous, and mesoporous conditions may be analyzed using this technique. Typical standard deviations for full isotherm fits including porous samples are less than 2%. Notice that in this description of physical adsorption, the entropy of adsorption is consistent with the Dubinin thermodynamic criterion, that is the entropy of adsorption from the liquid state to the adsorbed state is approximately zero.

=== First Trump administration (2017–2021) === On August 13, 2018, Section 1051 of the Fiscal Year 2019 John S. McCain National Defense Authorization Act (P.L. 115-232) established the National Security Commission on Artificial Intelligence "to consider the methods and means necessary to advance the development of artificial intelligence, machine learning, and associated technologies to comprehensively address the national security and defense needs of the United States." Steering on regulating security-related AI is provided by the National Security Commission on Artificial Intelligence. The Artificial Intelligence Initiative Act (S.1558) is a proposed bill that would establish a federal initiative designed to accelerate research and development on AI for, inter alia, the economic and national security of the United States. On January 7, 2019, following an Executive Order on Maintaining American Leadership in Artificial Intelligence, the White House's Office of Science and Technology Policy released a draft Guidance for Regulation of Artificial Intelligence Applications, which includes ten principles for United States agencies when deciding whether and how to regulate AI. In response, the National Institute of Standards and Technology (NIST) released a position paper, and the Defense Innovation Board issued recommendations on the ethical use of AI. A year later, the administration called for comments on regulation in another draft of its Guidance for Regulation of Artificial Intelligence Applications.

== Structure == Cyclotides have a well-defined three-dimensional structure due to their interlocking disulfide bonds and cyclic peptide backbone. Backbone loops and selected residues are labeled on the structure to help orientation. The amino acid sequence (single-letter amino acid representation) for this peptide is indicated on the sequence diagram to the right. One of the interesting features of cyclic peptides is that knowledge of the peptide sequence does not reveal the ancestral head and tail; knowledge of the gene sequence is required for this. In the case of kalata B1 the indicated glycine (G) and asparagine (N) amino acids are the terminal residues that are linked in a peptide bond to cyclize the peptide.

=== Barriers to access === In the US, the list price for a long-acting injectable form is five to 20 times as much as a daily pill. This has reduced the number of people who are able to get a single monthly dose, instead of daily pills. Some jails consider the more expensive form a positive tradeoff: a single monthly injection may be simpler and easier for the staff to manage than daily trips to the dispensary to have a nurse provide a pill and make sure that it has been swallowed.

Adalimumab, sold under the brand name Humira and others, is a disease-modifying antirheumatic drug and monoclonal antibody used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis. It is administered by subcutaneous injection (injection under the skin). It works by inactivating tumor necrosis factor (TNF). Common side effects include upper respiratory tract infections, pain at the site of injection, rash, and headache. Other side effects may include serious infections, cancer, anaphylaxis, reactivation of hepatitis B, new onset or exacerbation of demyelinating diseases (such as multiple sclerosis), heart failure, liver failure, and aplastic anemia. Use during pregnancy is not recommended, but some sources show use during breastfeeding may be safe. Adalimumab was approved for medical use in the United States in 2002. It is on the World Health Organization's List of Essential Medicines. It is available as a biosimilar medication. In 2023, it was the 244th most commonly prescribed medication in the United States, with more than 3 million prescriptions.

Sources: en.wikipedia.org

Further detail

Methysticin is one of the six major kavalactones found in the kava plant. It enhances the activity of the GABAA receptor, acting as a positive modulator without affecting the benzodiazepine binding site. This effect is attributed to structural features such as its angular lactone ring and is similar in strength to other kavalactones like kavain and dihydromethysticin. Methysticin also induces the liver enzyme CYP1A1, which plays a role in the toxification of benzo[a]pyrene into a highly carcinogenic metabolite. However, such induction has not been observed in vivo in humans or animals. Additionally, methysticin is a mechanism-based inactivator of CYP2C9, irreversibly inhibiting the enzyme through NADPH-dependent reactive intermediates, suggesting potential interactions with medications metabolized by CYP2C9.

A range of algal morphologies is exhibited, and convergence of features in unrelated groups is common. The only groups to exhibit three-dimensional multicellular thalli are the reds and browns, and some chlorophytes. Apical growth is constrained to subsets of these groups: the florideophyte reds, various browns, and the charophytes. The form of charophytes is quite different from those of reds and browns, because they have distinct nodes, separated by internode 'stems'; whorls of branches reminiscent of the horsetails occur at the nodes. Conceptacles are another polyphyletic trait; they appear in the coralline algae and the Hildenbrandiales, as well as the browns. Most of the simpler algae are unicellular flagellates or amoeboids, but colonial and nonmotile forms have developed independently among several of the groups. Some of the more common organizational levels, more than one of which may occur in the lifecycle of a species, are

There is no scientific evidence that HCG is effective in the treatment of obesity. The meta-analysis found insufficient evidence supporting the claims that HCG is effective in altering fat-distribution, hunger reduction, or in inducing a feeling of well-being. The authors stated "…the use of HCG should be regarded as an inappropriate therapy for weight reduction…" In the authors opinion, "Pharmacists and physicians should be alert on the use of HCG for Simeons therapy. The results of this meta-analysis support a firm standpoint against this improper indication. Restraints on physicians practicing this therapy can be based on our findings." According to the American Society of Bariatric Physicians, no new clinical trials have been published since the definitive 1995 meta-analysis. The scientific consensus is that any weight loss reported by individuals on an "HCG diet" may be attributed entirely to the fact that such diets prescribe calorie intake of between 500 and 1,000 calories per day, substantially below recommended levels for an adult, to the point that this may risk health effects associated with malnutrition.

== Description == A creeping perennial plant which can reach heights of up to 20 cm (7.9 in). Its trailing stems can root at the nodes, which allows the species to reproduce via vegetative reproduction. The palmate leaves are hairless, attached to long stalks and are divided into 5 to 7 leaflets, with small green leaf-like stipules at the base. The plant blooms between June and September in Europe with flowers that are about 7 mm to 11 mm in diameter with heart-shaped yellow petals. Long stalks support these solitary yellow flowers consisting of 5 petals and sepals with a large number of stamens and carpels at the centre. There are also 5 epicalyx segments, giving the appearance of 10 sepals.

=== Union Government Ministry of Cooperation === The Union Ministry of Cooperation is a ministry under the Government of India which was formed in July 2021. The ministry provides a separate administrative, legal and policy framework for strengthening the cooperative movement in the country. The ministry's creation was announced on 6 July 2021 along with its vision statement of "Sahkar se samriddhi" (transl. Prosperity through cooperation). Before the creation of this ministry, the objectives of this ministry were looked after by the Ministry of Agriculture. The ministry works in strengthening cooperatives at the grassroot level, working to streamline processes for 'Ease of doing business' for cooperatives and enabling the development of Multi-State Co-operatives (MSCS). The same was initially announced by Finance Minister Nirmala Sitharaman while presenting the 2021 Union budget. The ministry was created with objectives of:

Sources: en.wikipedia.org

Supporting material

Potential fields of BSG application include ultra-sensitive detectors, high-performance catalytic cells, nanochannels for DNA sequencing and manipulation, high-performance heat sinking surfaces, rechargeable batteries of enhanced performance, nanomechanical resonators, electron multiplication channels in emission Nano-electronic devices, high-capacity sorbents for safe hydrogen storage. Three dimensional bilayer graphene has also been reported.

==== Indirect immunofluorescence (IDIF) ==== Patients with high concentration of antibodies show intercellular, intraepidermal antibodies as well as along the dermoepidermal junction. Patients with low concentration of antibodies only present with them inside the cells (intercellular). If the results are negative, perform the additional assays regardless. Cases have been confirmed that reported with initial negative DIF and IDIF tests.

== Structure and ligand binding == The H-type pseudoknot core of mini-NAD⁺-II aptamers is structurally analogous to that of the preQ1-I riboswitch class, one of the smallest known natural riboswitch aptamers. Both classes represent the shortest known natural RNA aptamers, yet achieve high ligand-binding specificity. This structural similarity suggests that simple H-type pseudoknots may function as versatile scaffolds for constructing ligand-binding aptamers, either naturally or synthetically. Biochemical analysis using in-line probing confirmed that mini-NAD⁺-II RNAs bind both NAD⁺ and NMN, with strong preference for NMN. Biochemical analysis using in-line probing confirmed that mini-NAD⁺-II RNAs bind both NAD⁺ and NMN, with strong preference for NMN. Mini-NAD⁺-II aptamers discriminate more strongly between NMN and NAD⁺ than the larger P1a containing aptamers, likely because they lack the conserved adenosines flanking P1a that make non-specific contacts with the adenosine moiety of NAD⁺. Gene Regulation NAD⁺-II and mini-NAD⁺-II riboswitches are predicted to function as translational "OFF" switches: when NAD⁺ or NMN concentrations are sufficiently high, the riboswitch ligand-bound conformation sequesters the Shine-Dalgarno sequence within a pseudoknot, preventing ribosome binding and repressing translation of the downstream gene. The downstream genes regulated by NAD⁺-II and mini-NAD⁺-II riboswitches include:

Mazowiecki decided to leave the economic reform entirely in the hands of economic liberals led by the new Deputy Prime Minister Leszek Balcerowicz, who proceeded with the design and implementation of his "shock therapy" policy. For the first time in post-war history, Poland had a government led by non-communists, setting a precedent soon to be followed by other Eastern Bloc nations in a phenomenon known as the Revolutions of 1989. Mazowiecki's acceptance of the "thick line" formula meant that there would be no "witch-hunt", i.e., an absence of revenge seeking or exclusion from politics in regard to former communist officials. In part because of the attempted indexation of wages, inflation reached 900% by the end of 1989, but was soon dealt with by means of radical methods. In December 1989, the Sejm approved the Balcerowicz Plan to transform the Polish economy rapidly from a centrally planned one to a free market economy.[v] The Constitution of the Polish People's Republic was amended to eliminate references to the "leading role" of the communist party and the country was renamed the "Republic of Poland". The communist Polish United Workers' Party dissolved itself in January 1990. In its place, a new party, Social Democracy of the Republic of Poland, was created. "Territorial self-government", abolished in 1950, was legislated back in March 1990, to be led by locally elected officials; its fundamental unit was the administratively independent gmina.[q] In October 1990, the constitution was amended to curtail the term of President Jaruzelski.

In humans, glucose is metabolized by glycolysis and the pentose phosphate pathway. Glycolysis is used by all living organisms, with small variations, and all organisms generate energy from the breakdown of monosaccharides. In the further course of the metabolism, it can be completely degraded via oxidative decarboxylation, the citric acid cycle (synonym Krebs cycle) and the respiratory chain to water and carbon dioxide. If there is not enough oxygen available for this, the glucose degradation in animals occurs anaerobic to lactate via lactic acid fermentation and releases much less energy. Muscular lactate enters the liver through the bloodstream in mammals, where gluconeogenesis occurs (Cori cycle). With a high supply of glucose, the metabolite acetyl-CoA from the Krebs cycle can also be used for fatty acid synthesis. Glucose is also used to replenish the body's glycogen stores, which are mainly found in liver and skeletal muscle. These processes are hormonally regulated. In other living organisms, other forms of fermentation can occur. The bacterium Escherichia coli can grow on nutrient media containing glucose as the sole carbon source. In some bacteria and, in modified form, also in archaea, glucose is degraded via the Entner-Doudoroff pathway. With glucose, a mechanism for gene regulation was discovered in E. coli, the catabolite repression (formerly known as glucose effect). Use of glucose as an energy source in cells is by either aerobic respiration, anaerobic respiration, or fermentation.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.

Is SR9009 a steroid?

No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.

Has SR9009 been tested in humans?

Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.

What is SR9009?

SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.

Network